A REVIEW ON FINGOLIMOD; THE FIRST ORAL MEDICATION FOR MULTIPLE SCLEROSIS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AMIRIMOGHADAM P.; ALIMARDANZADEH M.; SABOURI S.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES Year:2018 | Volume:17 | Issue:1 Page(s): 63-74

Download Full-Text

Persian Verion

View:

926

Download:

Cites:

Information Journal Paper

Title

A REVIEW ON FINGOLIMOD; THE FIRST ORAL MEDICATION FOR MULTIPLE SCLEROSIS

Author(s)

AMIRIMOGHADAM P. | ALIMARDANZADEH M. | SABOURI S. | Issue Writer Certificate

Keywords

RELAPSING-REMITTING MULTIPLE SCLEROSISQ1

FINGOLIMODQ1

SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORSQ1

Abstract

Multiple sclerosis (MS) is a progressive neurological autoimmune disease that usually starts in the late third and early forth decades of life. Demyelination of neurons in the central nervous system (CNS) and, subsequently, loss of nerve cells is the known disease pathogenesis. The disease is controlled by a class of medicines which are mainly immunomodulators. FINGOLIMOD (FIN) is the first approved oral medication for controlling relapsingremitting type of MS. It is chemically modified form of a fungus metabolite with long history of use in traditional Chinese medicine. Its mechanism of action is through functional antagonism of sphingosine-1 phosphate receptors which leads to lymphocyte entrapment in lymphoid tissues and reduction of their circulating number in the CNS. FIN efficacy comparing with placebo and first line therapies for MS (e.g. Interferon) has been proved through several clinical trials. Common side effects of FIN are usually mild and are well tolerated.FIN can pass through placenta and has been assigned to pregnancy category C according to the observed effects in animal studies. Since the drug molecule is secreted into milk, lactation during consumption is not recommended. Considering oral administration and mild side effects of FIN, it can be useful in management of MS. However, due to the incidence of some rare but serious adverse effects such as systemic viral infections, macular edema, and cardiovascular complications, physicians should investigate patient’s clinical status and underlying comorbidities carefully.

Cites

No record.

References

Cite

APA: Copy

AMIRIMOGHADAM, P., ALIMARDANZADEH, M., & SABOURI, S.. (2018). A REVIEW ON FINGOLIMOD; THE FIRST ORAL MEDICATION FOR MULTIPLE SCLEROSIS. JOURNAL OF RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES, 17(1 ), 63-74. SID. https://sid.ir/paper/71503/en

Vancouver: Copy

AMIRIMOGHADAM P., ALIMARDANZADEH M., SABOURI S.. A REVIEW ON FINGOLIMOD; THE FIRST ORAL MEDICATION FOR MULTIPLE SCLEROSIS. JOURNAL OF RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES[Internet]. 2018;17(1 ):63-74. Available from: https://sid.ir/paper/71503/en

IEEE: Copy

P. AMIRIMOGHADAM, M. ALIMARDANZADEH, and S. SABOURI, “A REVIEW ON FINGOLIMOD; THE FIRST ORAL MEDICATION FOR MULTIPLE SCLEROSIS,” JOURNAL OF RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES, vol. 17, no. 1 , pp. 63–74, 2018, [Online]. Available: https://sid.ir/paper/71503/en

Related Journal Papers